Published in Antimicrob Agents Chemother on March 26, 2007
Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother (2007) 3.44
Predictors of positive blood culture and deaths among neonates with suspected neonatal sepsis in a tertiary hospital, Mwanza-Tanzania. BMC Pediatr (2010) 2.06
Extraintestinal Pathogenic Escherichia coli: A Combination of Virulence with Antibiotic Resistance. Front Microbiol (2012) 1.98
Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance. Antimicrob Agents Chemother (2015) 1.95
Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Chemother (2009) 1.91
ESBLs: A Clear and Present Danger? Crit Care Res Pract (2011) 1.77
Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum β-lactamase-producing Escherichia coli causing bacteremia in a centralized Canadian region. J Clin Microbiol (2011) 1.67
Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother (2010) 1.47
Clinical characteristics of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type β-lactamases. Clin Microbiol Infect (2011) 1.39
In vitro blood culture bottle inoculation of whole blood with clinically relevant antibiotic concentrations: a word of caution. Eur J Clin Microbiol Infect Dis (2016) 1.38
Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother (2011) 1.29
Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother (2008) 1.27
Ertapenem resistance among extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae isolates. J Clin Microbiol (2009) 1.21
Antimicrobial resistance in hospitals: how concerned should we be? CMAJ (2009) 1.16
Hypermucoviscosity as a virulence factor in experimental Klebsiella pneumoniae endophthalmitis. Invest Ophthalmol Vis Sci (2008) 1.10
Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother (2012) 1.10
Antimicrobial stewardship program directed at broad-spectrum intravenous antibiotics prescription in a tertiary hospital. Eur J Clin Microbiol Infect Dis (2009) 1.04
Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria. Antimicrob Agents Chemother (2013) 0.99
Multidrug-resistant Proteus mirabilis bloodstream infections: risk factors and outcomes. Antimicrob Agents Chemother (2012) 0.96
Decreased susceptibility to noncarbapenem antimicrobials in extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in Toronto, Canada. Antimicrob Agents Chemother (2012) 0.96
Extended Spectrum-β-Lactamase or Carbapenemase Producing Bacteria Isolated from Patients with Acute Cholangitis. Clin Endosc (2012) 0.95
Fluoroquinolone-resistant Escherichia coli sequence type 131 isolates causing bloodstream infections in a canadian region with a centralized laboratory system: rapid emergence of the H30-Rx sublineage. Antimicrob Agents Chemother (2014) 0.95
Characterization of TEM-1 β-lactamase producing Kingella kingae clinical isolates. Antimicrob Agents Chemother (2013) 0.94
Increase in hospital-acquired bloodstream infections caused by extended spectrum beta-lactamase-producing Escherichia coli in a large French teaching hospital. Eur J Clin Microbiol Infect Dis (2008) 0.94
Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients. Antimicrob Agents Chemother (2010) 0.93
Non-phenotypic tests to detect and characterize antibiotic resistance mechanisms in Enterobacteriaceae. Diagn Microbiol Infect Dis (2013) 0.93
Rapid identification of gram-negative bacteria with and without CTX-M extended-spectrum β-lactamase from positive blood culture bottles by PCR followed by microchip gel electrophoresis. J Clin Microbiol (2011) 0.92
Enterohemorrhagic Escherichia coli as causes of hemolytic uremic syndrome in the Czech Republic. PLoS One (2013) 0.92
Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica (2011) 0.90
Antibiotic consumption and its influence on the resistance in Enterobacteriaceae. BMC Res Notes (2014) 0.89
The clinical impact of multidrug-resistant gram-negative bacilli in the management of septic shock. Virulence (2013) 0.89
Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum β-lactamase-producing enterobacteriaceae on hospital admission. Infect Control Hosp Epidemiol (2013) 0.89
Population-based incidence and comparative demographics of community-associated and healthcare-associated Escherichia coli bloodstream infection in Auckland, New Zealand, 2005-2011. BMC Infect Dis (2013) 0.89
Plasmid-mediated AmpC: prevalence in community-acquired isolates in Amsterdam, the Netherlands, and risk factors for carriage. PLoS One (2015) 0.89
Clinical management of infections caused by multidrug-resistant Enterobacteriaceae. Ther Adv Infect Dis (2013) 0.88
Pretransplant fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae and infection after liver transplant, France. Emerg Infect Dis (2012) 0.88
Risk factors for gastrointestinal tract colonization with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella species in hospitalized patients. Infect Control Hosp Epidemiol (2012) 0.88
Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility. Antimicrob Agents Chemother (2012) 0.87
Resistance trends in gram-negative bacteria: surveillance results from two Mexican hospitals, 2005-2010. BMC Res Notes (2012) 0.87
Evaluation of a Commercial Multiplex PCR for Rapid Detection of Multi Drug Resistant Gram Negative Infections. Open Microbiol J (2015) 0.86
Predictive models for identification of hospitalized patients harboring KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother (2014) 0.85
New Insight on Epidemiology and Management of Bacterial Bloodstream Infection in Patients with Hematological Malignancies. Mediterr J Hematol Infect Dis (2015) 0.85
Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum β-Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae. Infect Dis Ther (2015) 0.84
Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline. Ther Clin Risk Manag (2010) 0.84
Benefits of Adding a Rapid PCR-Based Blood Culture Identification Panel to an Established Antimicrobial Stewardship Program. J Clin Microbiol (2016) 0.84
Bloodstream infections and mortality-related factors in febrile neutropenic cancer patients. Med Sci Monit (2011) 0.84
Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute Infections. Infect Chemother (2016) 0.83
Risk factors for extended-spectrum beta-lactamase-producing Escherichia coli infection in hospitalized patients. Nagoya J Med Sci (2012) 0.81
Strategic measures for the control of surging antimicrobial resistance in Hong Kong and mainland of China. Emerg Microbes Infect (2015) 0.81
Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems. Eur J Clin Microbiol Infect Dis (2017) 0.80
Recent changes in the epidemiology and management of extended-spectrum β-lactamase-producing Enterobacteriaceae. F1000 Med Rep (2009) 0.80
How to treat severe infections in critically ill neutropenic patients? BMC Infect Dis (2014) 0.80
Phenotypic detection of broad-spectrum beta-lactamases in microbiological practice. Med Sci Monit (2011) 0.80
Bacteriology and drug susceptibility analysis of pus from patients with severe intra-abdominal infection induced by abdominal trauma. Exp Ther Med (2014) 0.79
Derivation and validation of a scoring system to identify patients with bacteremia and hematological malignancies at higher risk for mortality. PLoS One (2012) 0.79
Urinary Tract Infections in Kidney Transplant Patients Due to Escherichia coli and Klebsiella pneumoniae-Producing Extended-Spectrum β-Lactamases: Risk Factors and Molecular Epidemiology. PLoS One (2015) 0.78
Designer aminoglycosides prevent cochlear hair cell loss and hearing loss. J Clin Invest (2015) 0.78
Epidemiology and Burden of Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae in a Pediatric Hospital in Senegal. PLoS One (2016) 0.78
Polyclonal spread and outbreaks with ESBL positive gentamicin resistant Klebsiella spp. in the region Kennemerland, The Netherlands. PLoS One (2014) 0.78
In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli. Eur J Clin Microbiol Infect Dis (2011) 0.78
Risk factors and molecular epidemiology of community-onset extended-spectrum β-lactamase-producing Escherichia coli bacteremia. Yonsei Med J (2014) 0.78
Multidrug-resistant bacterial infections after liver transplantation: an ever-growing challenge. World J Gastroenterol (2014) 0.78
Infections caused by extended-spectrum beta-lactamases producing Enterobacteriaceae: clinical and economic impact in patients hospitalized in 2 teaching hospitals in Dakar, Senegal. Antimicrob Resist Infect Control (2016) 0.77
Genomic and Functional Portrait of a Highly Virulent, CTX-M-15-Producing H30-Rx Subclone of Escherichia coli Sequence Type 131. Antimicrob Agents Chemother (2015) 0.77
The strategy of antibiotic use in critically ill neutropenic patients. Ann Intensive Care (2011) 0.77
Sepsis Caused by Extended-Spectrum Beta-Lactamase (ESBL)-Positive K. pneumoniae and E. coli: Comparison of Severity of Sepsis, Delay of Anti-Infective Therapy and ESBL Genotype. PLoS One (2016) 0.77
ESBL Detection: Comparison of a Commercially Available Chromogenic Test for Third Generation Cephalosporine Resistance and Automated Susceptibility Testing in Enterobactericeae. PLoS One (2016) 0.76
Clinical usefulness of the 2010 clinical and laboratory standards institute revised breakpoints for cephalosporin use in the treatment of bacteremia caused by Escherichia coli or Klebsiella spp. Biomed Res Int (2015) 0.76
Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study. BMC Infect Dis (2017) 0.75
Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae. Antibiotics (Basel) (2015) 0.75
Direct RNA-based detection and differentiation of CTX-M-type extended-spectrum β-lactamases (ESBL). PLoS One (2013) 0.75
Aminoglycoside Resistance in Clinical Isolates of Gram Negative Bacilli at the University Hospital of the West Indies, Jamaica: Comparison of Two Time Periods. West Indian Med J (2015) 0.75
Carriage of Class 1 and 2 Integrons in Quinolone, Extended-Spectrum-β-Lactamase-Producing and Multi Drug Resistant E.coli and K.pneumoniae: High Burden of Antibiotic Resistance. Adv Pharm Bull (2015) 0.75
Prevalence of ESBL-Producing Enterobacteriaceae in Pediatric Bloodstream Infections: A Systematic Review and Meta-Analysis. PLoS One (2017) 0.75
Frequency, Antimicrobial Resistance and Genetic Diversity of Klebsiella pneumoniae in Food Samples. PLoS One (2016) 0.75
In silico serine β-lactamases analysis reveals a huge potential resistome in environmental and pathogenic species. Sci Rep (2017) 0.75
Influence of antibiotic-regimens on intensive-care unit-mortality and liver-cirrhosis as risk factor. World J Gastroenterol (2016) 0.75
The Use of Bloodstream Infection Mortality to Measure the Impact of Antimicrobial Stewardship Interventions: Assessing the Evidence. Infect Dis Rep (2017) 0.75
Clinical and microbiological determinants of severe and fatal outcomes in patients infected with Enterobacteriaceae producing extended-spectrum β-lactamase. Eur J Clin Microbiol Infect Dis (2017) 0.75
The Role of Adjunctive Therapies in Septic Shock by Gram Negative MDR/XDR Infections. Can J Infect Dis Med Microbiol (2017) 0.75
Antimicrobial use and microbiological testing in district general hospital ICUs of the Veneto region of north-east Italy. Eur J Clin Microbiol Infect Dis (2016) 0.75
Association between dementia and reduced walking ability and 30-day mortality in patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia. Eur J Clin Microbiol Infect Dis (2017) 0.75
A Role for FimH in Extraintestinal Pathogenic Escherichia coli Invasion and Translocation through the Intestinal Epithelium. Infect Immun (2017) 0.75
Transcriptional Alterations of Virulence-Associated Genes in Extended Spectrum Beta-Lactamase (ESBL)-Producing Uropathogenic Escherichia coli during Morphologic Transitions Induced by Ineffective Antibiotics. Front Microbiol (2017) 0.75
Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: A Systematic Review and Meta-Analysis. Open Forum Infect Dis (2017) 0.75
Fatal sepsis by Klebsiella pneumoniae in a patient with systemic lupus erythematosus: the importance of postmortem microbiological examination for the ex post diagnosis of infection. Int J Legal Med (2015) 0.75
Clinical management of ESBL-producing Enterobacteriaceae: the insidious role of fluoroquinolones. Eur J Clin Microbiol Infect Dis (2011) 0.75
Clinical impact of extended-spectrum β-lactamase-producing Enterobacteriaceae in patients with biliary tract infection. Dig Dis Sci (2012) 0.75
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79
CDC definitions for nosocomial infections, 1988. Am J Infect Control (1988) 27.03
The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest (1991) 16.06
Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev (2001) 15.81
Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev (2005) 15.72
Management of sepsis. N Engl J Med (2006) 9.01
qnrB, another plasmid-mediated gene for quinolone resistance. Antimicrob Agents Chemother (2006) 5.50
Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA (1999) 5.26
Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis (2001) 4.79
International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med (2004) 4.75
The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis (2006) 4.60
Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol (2001) 4.19
Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis (2006) 3.79
Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis (2004) 3.75
Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother (2006) 3.33
Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis (2000) 3.01
Phenotypic and molecular detection of CTX-M-beta-lactamases produced by Escherichia coli and Klebsiella spp. J Clin Microbiol (2004) 2.95
Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis (1996) 2.49
Multiple CTX-M-type extended-spectrum beta-lactamases in nosocomial isolates of Enterobacteriaceae from a hospital in northern Italy. J Clin Microbiol (2003) 2.45
gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob Agents Chemother (1998) 2.35
OXA-15, an extended-spectrum variant of OXA-2 beta-lactamase, isolated from a Pseudomonas aeruginosa strain. Antimicrob Agents Chemother (1997) 2.28
Spread of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: are beta-lactamase inhibitors of therapeutic value? Clin Infect Dis (1998) 2.20
Characteristics of bacteremia between community-acquired and nosocomial Klebsiella pneumoniae infection: risk factor for mortality and the impact of capsular serotypes as a herald for community-acquired infection. Arch Intern Med (2002) 2.19
Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother (2006) 2.07
Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother (2004) 2.02
Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis (2006) 1.99
Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase. J Clin Microbiol (2001) 1.92
Trends in production of extended-spectrum beta-lactamases among enterobacteria of medical interest: report of the second Italian nationwide survey. J Clin Microbiol (2006) 1.91
High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother (2005) 1.90
Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clin Infect Dis (2002) 1.88
Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection. Arch Intern Med (2005) 1.82
Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis (2001) 1.79
Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: antibiotic use as risk factor for colonization and infection. Clin Infect Dis (2000) 1.74
Virulence characteristics and phylogenetic background of multidrug-resistant and antimicrobial-susceptible clinical isolates of Escherichia coli from across the United States, 2000-2001. J Infect Dis (2004) 1.59
Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit. J Hosp Infect (1997) 1.58
Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother (2005) 1.55
OXA-17, a further extended-spectrum variant of OXA-10 beta-lactamase, isolated from Pseudomonas aeruginosa. Antimicrob Agents Chemother (1999) 1.49
Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis (2003) 1.41
Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect (2005) 1.41
Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother (2006) 1.31
Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis (2001) 1.20
ESBL-producing multidrug-resistant Providencia stuartii infections in a university hospital. J Antimicrob Chemother (2003) 1.20
A case-control study of an outbreak of infections caused by Klebsiella pneumoniae strains producing CTX-1 (TEM-3) beta-lactamase. J Hosp Infect (1991) 1.15
Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. Infect Control Hosp Epidemiol (2002) 1.12
Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother (2006) 1.10
Evaluation of the new VITEK 2 extended-spectrum beta-lactamase (ESBL) test for rapid detection of ESBL production in Enterobacteriaceae isolates. J Clin Microbiol (2006) 1.07
Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother (2006) 1.07
Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. J Antimicrob Chemother (2006) 0.87
Prosthetic joint infection: recent developments in diagnosis and management. J Infect (2010) 4.96
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis (2012) 4.62
A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med (2014) 3.56
Detection and Isolation of Mycobacterium avium subspecies paratuberculosis from intestinal mucosal biopsies of patients with and without Crohn's disease in Sardinia. Am J Gastroenterol (2005) 3.47
Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int J Antimicrob Agents (2007) 2.61
Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother (2005) 2.48
Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures. Clin Infect Dis (2010) 2.32
Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis (2003) 2.23
Rv1818c-encoded PE_PGRS protein of Mycobacterium tuberculosis is surface exposed and influences bacterial cell structure. Mol Microbiol (2004) 2.09
Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother (2006) 2.07
Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol (2007) 1.99
Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother (2007) 1.91
Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial. J Antimicrob Chemother (2006) 1.88
Mycobacterium avium subsp. paratuberculosis, genetic susceptibility to Crohn's disease, and Sardinians: the way ahead. J Clin Microbiol (2005) 1.82
Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. J Antimicrob Chemother (2010) 1.80
Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario. AIDS (2003) 1.77
Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog (2009) 1.76
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia. Antivir Ther (2013) 1.66
Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol (2003) 1.58
Direct maldi-tof mass spectrometry assay of blood culture broths for rapid identification of Candida species causing bloodstream infections: an observational study in two large microbiology laboratories. J Clin Microbiol (2011) 1.58
The quest for a new vaccine against tuberculosis. J Infect Dev Ctries (2009) 1.55
A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med (2015) 1.54
Recurrent ventriculoperitoneal shunt infection caused by small-colony variants of Staphylococcus aureus. Clin Infect Dis (2005) 1.53
Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (2002) 1.52
Comparative study of the physiological roles of three peroxidases (NADH peroxidase, Alkyl hydroperoxide reductase and Thiol peroxidase) in oxidative stress response, survival inside macrophages and virulence of Enterococcus faecalis. Mol Microbiol (2007) 1.51
Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother (2010) 1.47
Characterization of clinical isolates of Enterobacteriaceae from Italy by the BD Phoenix extended-spectrum beta-lactamase detection method. J Clin Microbiol (2003) 1.46
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy. AIDS Res Hum Retroviruses (2011) 1.45
Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother (2009) 1.40
Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score, and colonization index. Crit Care (2011) 1.38
Hemangiomas and other congenital malformations in infants exposed to antiretroviral therapy in utero. JAMA (2004) 1.38
ace, Which encodes an adhesin in Enterococcus faecalis, is regulated by Ers and is involved in virulence. Infect Immun (2009) 1.37
Comparative evaluation of the Bruker Biotyper and Vitek MS matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry systems for identification of yeasts of medical importance. J Clin Microbiol (2013) 1.36
Use of the VITEK 2 system for rapid identification of clinical isolates of Staphylococci from bloodstream infections. J Clin Microbiol (2003) 1.36
MALDI-TOF mass spectrometry in the clinical mycology laboratory: identification of fungi and beyond. Expert Rev Proteomics (2013) 1.36
PE is a functional domain responsible for protein translocation and localization on mycobacterial cell wall. Mol Microbiol (2007) 1.34
Evaluation of VITEK 2 and RapID yeast plus systems for yeast species identification: experience at a large clinical microbiology laboratory. J Clin Microbiol (2007) 1.33
In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother (2012) 1.29
Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother (2011) 1.29
Rapid screening tests for meticillin-resistant Staphylococcus aureus at hospital admission: systematic review and meta-analysis. Lancet Infect Dis (2009) 1.28
Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother (2008) 1.27
Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital. PLoS One (2012) 1.27
Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol (2011) 1.27
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology (2010) 1.26
The ATP-binding cassette transporter-encoding gene CgSNQ2 is contributing to the CgPDR1-dependent azole resistance of Candida glabrata. Mol Microbiol (2008) 1.26
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infect Dis (2012) 1.26